Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice
Environmental Toxicology and Pharmacology · 2023
DOI: 10.1016/j.etap.2023.104261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology and Pharmacology, 2023. Verfasst von Rania Gamal Elkatary und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Hauptthemen laut MEDLINE: Cardiomyopathies, Poly(ADP-ribose) Polymerase Inhibitors, Sarcoplasmic Reticulum Calcium-Transporting ATPases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: Materials and Energy Research Center.
Abstract (Originalsprache)
The cardiotoxicity induced by doxorubicin is dose-dependent. The present study tested the potential cardioprotective effect of Poly ADP Ribose Polymerase (PARP) pathway inhibitor "olaparib" in a mouse model of doxorubicin-induced cardiomyopathy (DOX-CM). Seventy-two male BALB/c mice were randomized into six equal groups; control, DOX-CM, dexrazoxane-treated, and three olaparib-treated groups (5, 10, and 50 mg/kg/day). Cardiomyopathy was assessed by heart weight/Tibial length (HW/TL) ratio, cardiac fibrosis, oxidative stress, and electron microscope. Myocardial expression of SERCA2a mRNA and cleaved PARP-1 protein were also assessed. Similar to dexrazoxane, olaparib (10 mg/kg/day) significantly ameliorated oxidative stress, and preserved cardiac structure. It also suppressed myocardial PARP-1 protein expression and boosted SERCA2a mRNA expression. Olaparib (5 or 50 mg/kg/day) failed to show comparable effects. The current study detected the cardioprotective effect of olaparib at a dosage of 10 mg/kg/day. Also, the present study discovered a new cardioprotective mechanism of dexrazoxane by targeting PARP-1 in the heart.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt.
- Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Egypt.
- Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt; Horus University-Egypt, New Damietta, Egypt.
- Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura 35516, Egypt. Electronic address: drrehab40@mans.edu.eg.
Förderung
- Materials and Energy Research Center
Zitieren
APA
Elkatary, R. G., El Beltagy, H. M., Abdo, V. B., El Fatah, D. S. A., El-Karef, A., & Ashour, R. H. (2023). Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. Environmental Toxicology and Pharmacology. https://doi.org/10.1016/j.etap.2023.104261
Vancouver
Elkatary RG, El Beltagy HM, Abdo VB, El Fatah DSA, El-Karef A, Ashour RH. Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. Environmental Toxicology and Pharmacology. 2023. doi:10.1016/j.etap.2023.104261
BibTeX
@article{Elkatary2023,
author = {Elkatary, Rania Gamal and El Beltagy, Hussein Mahmoud and Abdo, Vivian Boshra and El Fatah, Dina Sabry Abd and El-Karef, Amr and Ashour, Rehab Hamdy},
title = {Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice},
journal = {Environmental Toxicology and Pharmacology},
year = {2023},
doi = {10.1016/j.etap.2023.104261}
}
EUVIMED